COVID-19
Conditions
Brief summary
Traditional Chinese medicine (TCM) has been handed down for thousands of years. It has a long history in the treatment of virus infection and has a good effect on the upper respiratory tract infection. In recent years, the project applicant has been conducting research on the anti infection and anti inflammation treatment of traditional Chinese medicine, and has carried out a lot of clinical practice exploration in non-specific inflammation. The purpose of this research is to study the therapeutic effect of a traditional Chinese medicine prescription on COVID-19 infection.
Interventions
The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.
OTHERPlacebo Treatment
Placebo Treatment Group:The patient are given placebo, taking 150 ml of liquid placebo every morning and evening for 7 days. All medications and placebo are packed identically in packing bags with the same labeling form.
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* In the past two to three days, COVID-19 test was positive, accompanied by more than one clinical symptom. * 18 ≤ age ≤ 65, regardless of gender; * Patients have good follow-up compliance.
Exclusion criteria
* Human immunodeficiency virus - 1 infection and malignant tumors; Active cardiovascular, kidney, lung, liver, blood, digestive, neurological or psychiatric diseases; Recent acute respiratory symptoms (within 4 weeks) . * Any drug that may interfere with the evaluation (for example, other herbal products such as Lianhua Qingwen, immunosuppressants, anticoagulants), or a history of allergy or other adverse reactions to traditional Chinese medicine products. * Pregnant or lactating women. * Allergic constitution and allergy to multiple drugs. * According to the judgment of the investigator, the subject suffers from any disease that may endanger his safety or affect his compliance with the protocol, or other conditions that are not suitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| negative Covid-19 test result | in 7 days or after the intervention | negative test result |
| Disappearance or Improvement of the most common clinical symptoms | in 7 days or after the intervention | such as fever,cough,pharyngalgia |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Interleukin- 6 | in 7 days or after the intervention | Pg/ml |
| Procalcitonin | in 7 days or after the intervention | mg/L |
| erythrocyte sedimentation rate | in 7 days or after the intervention | mm/h |
| blood fat | in 7 days or after the intervention | mmol/L |
| Covid-19 antibody concentration | in 7 days or after the intervention | ng/ml |
| C-reactionprotein | in 7 days or after the intervention | mg/L |
Countries
China
Contacts
Primary ContactBingyin Shi
Backup ContactZixian Du, master
Outcome results
None listed